Navigation Links
NASDAQ Gives Dynatronics a Second Three-Month Extension for Minimum Bid Price Compliance
Date:12/29/2008

s is available at www.dynatronics.com.

This press release contains forward-looking statements. Those statements include references to the company's expectations and include specifically the reference in this press release to increased revenues through the DynaClub direct sales program and the reference to restoring profitability. Such statements are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Actual results may vary from the views expressed in the forward-looking statements contained in this release. The development and sale of the company's products are subject to a number of risks and uncertainties, including, but not limited to, changes in the regulatory environment, competitive factors, inventory risks due to shifts in market demand, market demand for the company's products, availability of financing at cost effective rates, and the risk factors listed from time to time in the company's SEC reports including, but not limited to, the report on Form 10-K for the year ended June 30, 2008.


'/>"/>
SOURCE Dynatronics Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
2. Memory Pharmaceuticals Regains Compliance with NASDAQ Market Capitalization Requirement
3. Mylan Announces Move to NASDAQ Stock Market
4. DATATRAK International, Inc. Receives Notice from NASDAQ
5. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
6. Memory Pharmaceuticals Receives NASDAQ Decisions
7. PAREXEL International to Present at NASDAQ OMX 22nd Investor Program
8. Keryx Biopharmaceuticals Receives Nasdaq Notification
9. Accuray Receives Nasdaq Notification Related to the Late Filing of Form 10-Q
10. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
11. Pharmos Corporation Announces Receipt of Nasdaq Noncompliance Letter
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 2Health News:New Blood Thinner Could Replace Warfarin to Fight Venous Clots 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 2Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 3Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 4Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 5Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 6Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 7Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 8Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 9Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 10Health News:New Data Support Long-term Use of Antiepileptic Drug Vimpat(R) (Lacosamide) (C-V) 11Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 2Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 3Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 4Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 5Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 6Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 7Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 8Health News:Stand Up To Cancer Funds High-risk/High-reward Cancer Research by 13 Young Scientists 9Health News:Prescient Medical, Inc. CEO Patricia Scheller to Speak at 'The Value of Innovation in Health Care,' a Galen Institute Conference 2Health News:Help Young Cancer Patients Enjoy Christmas This Season 2
Other Medicine News:Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 2Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 3Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 4Health News:People with Disabilities Seek Ways to Manage Higher Healthcare Costs 5Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 2Health News:Nationally Recognized Pediatric Healthcare System Chooses PureWellness for Employee Wellness Program 3Health News:LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients 2Health News:LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients 3Health News:LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients 4Health News:Scopus Adds Pre-Print Research Abstracts From Four Prestigious Publishers 2Health News:Scopus Adds Pre-Print Research Abstracts From Four Prestigious Publishers 3Health News:This old healthy house 2Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 2Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 3Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 4
Breaking Medicine Technology:Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 2Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 3Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 4Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine 5New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3European Lung Cancer Screening Trial Demonstrates New Inexpensive Strategy for Improving Accuracy of Diagnosis 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 1CMSA Announces New Model ACT Supporting Case Management Programs 55526 2CMSA Announces New Model ACT Supporting Case Management Programs 55526 3President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 1President Bill Clinton to Speak at Inaugural Chicago House Speaker Series Luncheon 55524 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 1Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 2Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 3Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 4Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 5Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 6Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 7Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 8Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 9Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 10Cardium Reports Non Healing Wounds Continue to Challenge Patients and Healthcare Providers 4907 11